In Tuesday's trading, shares of Oncothyreon Inc., that created big pace last year following the launch of a phase III experiment of a budding cancer vaccine, Stimuvax, plunged 120% to $2.09.

Oncothyreon Inc said its development partner Merck KGaA started a late-stage trial of its cancer vaccine in Asia with advanced non-small cell lung cancer (NSCLC), sending Oncothyreon shares up by 10 per cent.